New PROMMIS Study Reports Breakthrough in Identifying High-Risk Multiple Myeloma Patients with SKY92
In a remarkable breakthrough for cancer diagnostics, SkylineDx has reported significant findings from the PROMMIS study that showcase the effectiveness of the SKY92 gene expression profiling (GEP) classifier in recognizing high-risk patients with multiple myeloma. This innovative diagnostic approach was recently unveiled at the American Society of Hematology (ASH) conference, as announced by the company’s Chief Scientific Officer, Dr. Jvalini Dwarkasing.
The PROMMIS study was conducted across nine prestigious cancer centers in the United States, involving 251 newly diagnosed multiple myeloma patients. It aimed to assess the prognostic value of the SKY92 classifier compared to traditional methods that primarily rely on identifying cytogenetic aberrations, such as deletions or duplications of chromosomes. Dr. Noa Biran, an Associate Professor at Hackensack Meridian School of Medicine, led the presentation detailing these groundbreaking results.
Historically, multiple myeloma has posed significant challenges for clinicians due to its complex molecular characteristics and the existence of high-risk patient subsets that experience poor survival rates despite advancements in treatments.
Traditional risk assessments often focus on chromosomal abnormalities to determine prognosis, yet this study highlighted that such methods hold limited prognostic value. Exceptions are identified, specifically involving the 1q21 chromosomal anomaly, which only demonstrated prognostic significance in patients aged 65 and above. In stark contrast, the data obtained from SKY92 has proven to be a much stronger indicator of patient outcomes.
Among the findings, patients identified as having the SKY92 high-risk biomarker exhibited significantly worse progression-free survival rates, irrespective of any other genetic abnormalities present. This critical insight suggests that the SKY92 classifier could significantly refine our understanding of the disease and allow for earlier and more accurate identification of patients who might need more aggressive treatment protocols.
Moreover, the study further revealed the potential of combining SKY92 results with specific genetic markers such as gain(1q21), leading to even more precise prognostic insights. Patients flagged by both assessments were found to have some of the poorest outcomes, reinforcing the argument for integrating SKY92 into routine clinical practice.
Dr. Dwarkasing emphasized that the findings underline how the SKY92 test can dramatically enhance the treatment of multiple myeloma patients by providing a clearer means to classify high-risk profiles. This confidence allows physicians to tailor therapies more effectively, ultimately aiming for improved patient outcomes and quality of life.
This research represents a significant stride in the understanding and management of multiple myeloma, with the SKY92 biomarker acting as a pivotal addition to clinicians’ diagnostic arsenal. The results corroborate the growing focus on personalized medicine, as healthcare providers can utilize this advanced molecular diagnostic tool to improve care strategies for their patients.
SkylineDx expresses profound gratitude to the patients, healthcare professionals, and research teams who contributed to the success of the PROMMIS study. Their dedication and collaboration were essential in making these important findings possible.
In conclusion, the MMprofiler with SKY92 not only enhances the insights into the biological behavior of multiple myeloma but also highlights the pressing need to adopt advanced diagnostic methods in clinical settings. With ongoing improvements, we can aspire to better prognostications and tailored treatment approaches, which could transform the landscape of multiple myeloma care.
The PROMMIS study was conducted across nine prestigious cancer centers in the United States, involving 251 newly diagnosed multiple myeloma patients. It aimed to assess the prognostic value of the SKY92 classifier compared to traditional methods that primarily rely on identifying cytogenetic aberrations, such as deletions or duplications of chromosomes. Dr. Noa Biran, an Associate Professor at Hackensack Meridian School of Medicine, led the presentation detailing these groundbreaking results.
Historically, multiple myeloma has posed significant challenges for clinicians due to its complex molecular characteristics and the existence of high-risk patient subsets that experience poor survival rates despite advancements in treatments.
Traditional risk assessments often focus on chromosomal abnormalities to determine prognosis, yet this study highlighted that such methods hold limited prognostic value. Exceptions are identified, specifically involving the 1q21 chromosomal anomaly, which only demonstrated prognostic significance in patients aged 65 and above. In stark contrast, the data obtained from SKY92 has proven to be a much stronger indicator of patient outcomes.
Among the findings, patients identified as having the SKY92 high-risk biomarker exhibited significantly worse progression-free survival rates, irrespective of any other genetic abnormalities present. This critical insight suggests that the SKY92 classifier could significantly refine our understanding of the disease and allow for earlier and more accurate identification of patients who might need more aggressive treatment protocols.
Moreover, the study further revealed the potential of combining SKY92 results with specific genetic markers such as gain(1q21), leading to even more precise prognostic insights. Patients flagged by both assessments were found to have some of the poorest outcomes, reinforcing the argument for integrating SKY92 into routine clinical practice.
Dr. Dwarkasing emphasized that the findings underline how the SKY92 test can dramatically enhance the treatment of multiple myeloma patients by providing a clearer means to classify high-risk profiles. This confidence allows physicians to tailor therapies more effectively, ultimately aiming for improved patient outcomes and quality of life.
This research represents a significant stride in the understanding and management of multiple myeloma, with the SKY92 biomarker acting as a pivotal addition to clinicians’ diagnostic arsenal. The results corroborate the growing focus on personalized medicine, as healthcare providers can utilize this advanced molecular diagnostic tool to improve care strategies for their patients.
SkylineDx expresses profound gratitude to the patients, healthcare professionals, and research teams who contributed to the success of the PROMMIS study. Their dedication and collaboration were essential in making these important findings possible.
In conclusion, the MMprofiler with SKY92 not only enhances the insights into the biological behavior of multiple myeloma but also highlights the pressing need to adopt advanced diagnostic methods in clinical settings. With ongoing improvements, we can aspire to better prognostications and tailored treatment approaches, which could transform the landscape of multiple myeloma care.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.